Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance

International Journal of Antimicrobial Agents

Volumn 40, Issue 5, 2012, Pages 381-388

  Kashiwagi, Seizaburo ^a   Yoshida, Sanae ^b   Yamaguchi, Hiroki ^b   Niwa, Shinpei ^b   Mitsui, Noriko ^b   Tanigawa, Masatoshi ^b   Shiosakai, Kazuhito ^b   Yamanouchi, Naoki ^b   Shiozawa, Tomoo ^b   Yamaguchi, Fumie ^b  

^a Kashiwagi Clinic   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

Abnormal behaviour; Laninamivir; Post marketing surveillance; Safety

Indexed keywords

LANINAMIVIR OCTANOATE;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABNORMAL BEHAVIOR; ABNORMAL DREAMING; ABNORMAL SENSATION; ADULT; AGE DISTRIBUTION; AGED; ANOREXIA; ASTHENOPIA; BACKACHE; CHILD; CONJUNCTIVAL HYPEREMIA; CONNECTIVE TISSUE DISEASE; COUGHING; CRYING; DELIRIUM; DIARRHEA; DISEASE DURATION; DIZZINESS; DRUG ERUPTION; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; ECZEMA; ENTERITIS; EYE DISEASE; FEAR; FEMALE; FEVER; GASTRITIS; GASTROENTERITIS; GASTROINTESTINAL DISEASE; HALLUCINATION; HEADACHE; HEART DISEASE; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HEPATOBILIARY DISEASE; HUMAN; HYPERTRANSAMINASEMIA; HYPESTHESIA; HYPOTHERMIA; INFESTATION; INFLUENZA; INNER EAR DISEASE; KIDNEY DISEASE; LIMB PAIN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; MOOD CHANGE; MOUTH PAIN; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NOCTURIA; NUTRITIONAL DISORDER; ORAL PARESTHESIA; OTALGIA; PHOBIA; POLLAKISURIA; POSITIONAL DIZZINESS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROTEINURIA; RESPIRATORY TRACT DISEASE; RESTLESSNESS; REVIEW; RHINOPHARYNGITIS; RISK ASSESSMENT; RISK FACTOR; SALIVARY GLAND PAIN; SCHOOL CHILD; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SLEEP DISORDER; STOMATITIS; THORAX DISEASE; UPPER ABDOMINAL PAIN; UROGENITAL TRACT DISEASE; URTICARIA; VERTIGO; VOMITING;

EID: 84867403055     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.06.017     Document Type: Short Survey

References (29)

1. A. Lackenby, O. Hungers, S.G. Dudman, A. Meijer, W.J. Paget, and A.J. Hay Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe Euro Surveill 13 2008 1 2
2. Analysis of seasonal and new influenza virus isolated in 2008 and 2009. http://idsc.nih.go.jp/iasr/30/357/dj3571.html#sect3. [accessed 03.07.12].
3. World Health Organization. Influenza A(H1N1) virus resistance to oseltamivir. Geneva, Switzerland: WHO. http://www.who.int/influenza/patient- care/antivirals/oseltamivir-summary/en/. [accessed 03.07.12].
4. US Centers for Disease Control and Prevention. 2008-2009 Influenza season week 17 ending May 2, 2009. Atlanta, GA: CDC. http://www.cdc.gov/h1n1flu/pubs/ pdf/FluView-Week17.pdf. [accessed 03.07.12].
5. E.C. Claas, A.D. Osterhaus, R. van Beek, J.C. De Jong, G.F. Rimmelzwaan, and D.A. Senne Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus Lancet 351 1998 472 477
6. A. Kandeel, S. Manoncourt, E. Abd el Kareem, A.N. Mohamed Ahmed, S. EI-Refaie, and H. Essmat Zoonotic transmission of avian influenza virus (H5N1). Egypt, 2006-2009 Emerg Infect Dis 16 2010 1101 1107
7. World Health Organization. Pandemic (H1N1) 2009 - update 105. Geneva, Switzerland: WHO. http://www.who.int/csr/don/2010-06-18/en/index.html. [accessed 02.07.12].
8. IASR. Prevalence of oseltamivir-resistant novel influenza (A/H1N1pdm) isolates (H275Y) in Japan - second report. http://idsc.nih.go.jp/iasr/31/364/ pr3641.html. [accessed 03.07.12].
9. Kenko-Nippon 21 forum: survey on influenza. http://www.kenko- nippon21forum.gr.jp/free/prerelease/contents031.pdf. [accessed 03.07.12].
10. M. Kiso, K. Mitamura, Y. Sakai-Tagawa, K. Shiraishi, C. Kawakami, and K. Kimura Resistant influenza A viruses in children treated with oseltamivir: descriptive study Lancet 364 2004 759 765
11. S. Hatakeyama, N. Sugaya, M. Ito, M. Yamazaki, M. Ichikawa, and K. Kimura Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors JAMA 297 2007 1435 1442
12. M. Yamashita, T. Tomozawa, M. Kakuta, A. Tokumitsu, H. Nasu, and S. Kubo CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity Antimicrob Agents Chemother 53 2009 186 192
13. S. Kubo, T. Tomozawa, M. Kakuta, M. Kakuta, A. Tokumitsu, and M. Yanashita Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration Antimicrob Agents Chemother 54 2010 1256 1264
14. Y. Itoh, K. Shinya, M. Kiso, T. Watanabe, Y. Sakoda, and M. Hatta In vitro and in vivo characterization of new swine-origin H1N1 influenza virus Nature 460 2009 1021 1025
15. M. Kiso, S. Kubo, M. Ozark, Q. Male Le, C.A. Nimrod, and M. Yamashita Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses PLoS Pathog 6 2010 e1000786
16. N. Sugaya, and Y. Hashish Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection Antimicrob Agents Chemother 54 2010 2575 2582
17. A. Watanabe, S.C. Chang, M.J. Kim, D.W. Chu, Y. Ohashi MARVEL Study Group Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial Clin Infect Dis 51 2010 1167 1175
18. S. Yokota, T. Fujita, M. Mori, A. Nezu, A. Okumura, and M. Hosoya Epidemiological survey of influenza-associated complications I. Clinical assessment of symptoms and signs, and medication Jap J Pediatric Infect 111 2007 1545 1558 [in Japanese]
19. K. Koyama, M. Takahashi, M. Oitate, N. Nakai, H. Takakusa, and S. Miura CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract Antimicrob Agents Chemother 53 2009 4845 4851
20. M. Yamashita, T. Hirai, K. Kubota, and S. Kubo Unique characteristics of long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) that explains its long-lasting activity Influenza Other Respir Viruses 5 Suppl. 1 2011 93 95
21. M. Yamashita Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitor for the treatment of influenza Antivir Chem Chemother 21 2010 74 84
22. Abnormal behavior after taking oseltamivir. http://www.mhlw.go.jp/houdou/ 2007/03/h0320-1.html. [accessed 03.07.12].
23. Reports on side effects in teenager with respect to cases with downfall and jumping off after taking oseltamivir. http://www.mhlw.go.jp/houdou/2007/03/ h0321-1.html. [accessed 03.07.12].
24. S. Toovey, C. Rayner, E. Prinssen, T. Chi, B. Donner, and B. Thakrar Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review Drug Saf 31 2008 1097 1114
25. N. Tomono, and H. Shiro The smaller number of influenza patients with neuropsychiatric events had taken oseltamivir beforehand Kansenshogaku Zasshi 82 2008 613 618 [in Japanese]
26. M. Tominaga, T. Tanabe, K. Hara, C. Kinoshita, T. Kasahara, and M. Kou Prospective studies on neurological symptoms associated with influenza virus infection during the 2006-2007 influenza season (part 2) - abnormal behaviors J Pediatr Infect Dis Immunol 19 2007 468 472
27. S. Jain, L. Kamimoto, A.M. Bramley, A.M. Schmitz, S.R. Benoit, and J. Louie Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009 N Engl J Med 361 2009 1935 1944
28. T. Fujita, M. Mori, A. Nezu, A. Okumura, M. Hosoya, and H. Suzuki Epidemiological survey of influenza-associated complications II. A statistical analysis of symptoms and signs, and medication Jap J Pediatr Infect 111 2007 1559 1567
29. T. Fujita, Y. Fujii, Y. Watanabe, H. Osaka, T. Wada, and M. Mori A pharmacoepidemiological study on the relationship between neuropsychiatric symptoms and therapeutic drugs after influenza infection Jpn J Pharmacoepidemiol 15 2010 73 95